Skip to content

TAG Reaction to the Price of GeneXpert Tests

Statement / Press • 2023
Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing major gaps in TB diagnosis.

TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis

Statement / Press • 2023
Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

Beyond Intellectual Property: Why Is Generic Treatment for HCV Still So Hard to Get

TAGline • 2023
By Joelle Dountio Ofimboudem and Sara Helena Gaspar Background Intellectual property is a major barrier to access to medicines worldwide because it creates corporate monopolies that restrict supply, keep prices high, and prevent people from accessing innovative health products. However, in the context of hepatitis C virus (HCV), intellectual property is no longer the major…

ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS

Statement / Press • 2023
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.

TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report

Statement / Press • 2023
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

Are We There Yet? TB Preventive Treatment Beyond TB/HIV Integration

TAGline • 2023
By Lynette Mabote-Eyde and Mike Frick Too often, major scientific advancements against tuberculosis (TB) get lost on the long and winding road of policy translation into practice. TB preventive treatment (TPT) has faced decades of dislocation between progressive global World Health Organization (WHO) guidance and lagging national-level guidelines and programmatic implementation. In some places, however,…

New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN

Statement / Press • 2023
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens

Statement / Press • 2023
Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands

Statement / Press • 2023
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

Statement / Press • 2022
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
Back To Top